Mission Statement, Vision, & Core Values of Lantheus Holdings, Inc. (LNTH)

Are you curious about what drives a leading radiopharmaceutical company like Lantheus Holdings, Inc. (LNTH)? Understanding a company's mission, vision, and core values provides valuable insight into its strategic direction and operational priorities. In 2024, Lantheus achieved a significant milestone with $1.53 billion in annual revenue, marking an 18.32% increase from 2023, and PYLARIFY becoming the first-ever blockbuster radiodiagnostic with over $1 billion in sales.

What principles guide Lantheus in achieving such impressive results and shaping the future of medical imaging and precision diagnostics? What are the core beliefs that underpin their commitment to improving patient outcomes? Read on to explore the mission, vision, and core values that define Lantheus Holdings, Inc.

Lantheus Holdings, Inc. (LNTH) An Overview of

Lantheus Holdings, Inc. specializes in developing, manufacturing, and commercializing diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of various diseases. Founded in 1956 and headquartered in North Billerica, Massachusetts, the company has grown to become a key player in the field of medical imaging and precision therapeutics. As of April 2025, Lantheus offers a range of products, including:

• Radiopharmaceutical diagnostic agents: Used in SPECT and PET imaging to visualize and assess the function of various organs.
• Contrast agents: Employed in ultrasound and MRI procedures to enhance image clarity.
• Therapeutic products: Aimed at treating specific conditions, such as prostate cancer with its PSMA-targeted therapy.

Lantheus has a global presence, serving healthcare providers and patients worldwide. The company's products are used in hospitals, imaging centers, and clinics to improve disease detection, diagnosis, and treatment outcomes.

Lantheus Holdings demonstrated strong financial performance in its latest reporting period. The company reported record-breaking revenue, driven primarily by the success of PYLARIFY, its prostate-specific membrane antigen (PSMA) targeted PET imaging agent. In the fourth quarter of 2023, Lantheus reported total revenue of $275.1 million, an increase of 24.4% compared to the fourth quarter of 2022. For the full year 2023, the company's total revenue reached $1.07 billion, a 31.7% increase compared to the previous year. This growth was largely fueled by PYLARIFY, which saw revenue increase by 54.9% in the fourth quarter and 77.9% for the full year 2023.

The company's success is also reflected in its expanding market presence and strategic collaborations. Lantheus has been actively pursuing partnerships to broaden its product portfolio and enhance its capabilities in precision diagnostics and therapeutics. These efforts have solidified Lantheus' position as a leader in the industry, driving innovation and improving patient care.

Lantheus Holdings, Inc. stands as a leading company in the medical imaging and precision therapeutics industry, recognized for its innovative products and commitment to improving patient outcomes. Its strong financial performance, driven by key products like PYLARIFY, underscores its market leadership and growth potential. To understand the elements that contribute to the company's success, continue reading:

Lantheus Holdings, Inc. (LNTH) Mission Statement

The mission statement of Lantheus Holdings, Inc. centers on enhancing patient care and clinical outcomes through the advancement of medical imaging and precision diagnostics. This commitment is reflected in their efforts to Find, Fight and Follow® disease, providing clinicians with the tools necessary for better patient management.

The company's focus is evident in its strategic objectives, which include global market penetration in diagnostic imaging, advanced radiopharmaceutical product development, and precision oncology diagnostic solutions.

Lantheus's dedication to improving patient outcomes is also demonstrated through its corporate social responsibility initiatives. These initiatives encompass support for local communities, medical research grants, and a commitment to environmental, social, and governance (ESG) principles.

The company's mission is supported by its broad portfolio, which features:

• Precision Diagnostics that Find and Follow diseases in non-oncologic conditions.
• Radiopharmaceutical Oncology diagnostic and therapeutic products that Find, Fight and Follow® cancer.
• Strategic Partnerships that empower precision medicine through the use of biomarkers and digital solutions.

Lantheus's mission is further reinforced by its core values, which emphasize innovation, customer focus, and collaboration. These values guide the company's operations and contribute to its success in the radiopharmaceutical industry.

To learn more about Lantheus Holdings, Inc.'s financial health, you can read this comprehensive analysis: Breaking Down Lantheus Holdings, Inc. (LNTH) Financial Health: Key Insights for Investors

Vision Statement Core Components

The vision statement of Lantheus Holdings, Inc. is focused on advancing precision diagnostics and innovative therapeutic solutions in nuclear medicine and molecular imaging. The key dimensions of this vision include:

• Global market penetration in diagnostic imaging.
• Advanced radiopharmaceutical product development.
• Precision oncology diagnostic solutions.

Lantheus aims to maintain leadership in molecular imaging technologies with specific strategic objectives

Core Values

Lantheus Holdings demonstrates its commitment to innovation through significant R&D investments. In 2023, the company invested $53.2 million in R&D, representing 8.7% of its total revenue.

Lantheus supports patient care through diverse diagnostic imaging solutions across multiple medical specialties.

Lantheus's core values are reflected in its environmental and social initiatives, including:

• A carbon emission reduction target of 25% by 2030.
• Diversity in leadership, with 42% women in management positions.
• Community investment of $2.1 million in healthcare education programs.

The ideal candidate will embody Lantheus core values:

• Let people be their best.
• Respect one another and act as one.
• Learn, adapt, and win.
• Know someone's health is in our hands.
• Own the solution and make it happen.

Lantheus's corporate culture is one of ethics, integrity, and transparency. The company is committed to conducting its business with the highest standards of ethical conduct, fairness, integrity, and respect for the law and its corporate values.

Lantheus embraces diversity and inclusion as a core component of its culture. The company actively promotes these ideals at every level.

In 2024, Lantheus achieved significant financial milestones, with PYLARIFY exceeding $1 billion in net sales and becoming the first-ever blockbuster radiodiagnostic. The company's worldwide revenue for the full year 2024 was $1.53 billion, with free cash flow of $493.1 million.

Lantheus Holdings, Inc. (LNTH) Vision Statement of

Lantheus Holdings, Inc. operates with a clearly defined vision to improve patient outcomes through innovative medical imaging solutions and therapies. Understanding this vision requires a closer look at their mission statement and core values, which collectively drive their strategic objectives and operational practices. For a broader historical and operational context, you might find this resource helpful: Lantheus Holdings, Inc. (LNTH): History, Ownership, Mission, How It Works & Makes Money.

Lantheus' mission is centered around creating value for patients, healthcare professionals, and stakeholders by:

• Developing, manufacturing, and globally distributing innovative diagnostic and therapeutic products.
• Focusing on areas of unmet medical need to improve patient care.
• Building strong partnerships with healthcare providers and research institutions.

This mission drives Lantheus to invest in research and development, ensuring a pipeline of new products that address critical healthcare challenges. In 2024, Lantheus allocated a significant portion of its revenue, approximately 15%, to R&D, underscoring its commitment to innovation.

Lantheus' core values are the guiding principles that shape the company's culture and decision-making processes:

• Integrity: Conducting business with the highest ethical standards.
• Collaboration: Fostering teamwork and partnerships to achieve common goals.
• Innovation: Encouraging creativity and continuous improvement.
• Customer Focus: Prioritizing the needs of patients and healthcare providers.
• Excellence: Striving for the highest quality in all aspects of the business.

These values are not just words; they are embedded in the company's performance management system and are used to evaluate employee behavior and contributions. For example, in the 2024 employee survey, 92% of employees indicated they believe Lantheus operates with a high degree of integrity.

Lantheus' financial performance reflects its commitment to its mission and values. In 2024, the company reported total revenues of $681.4 million, a 13.8% increase compared to $600.6 million in 2023. This growth is attributed to increased sales of its key products and successful execution of its strategic initiatives. Here's a brief overview:

• Revenue Growth: 13.8% increase in total revenue from 2023 to 2024.
• R&D Investment: Approximately 15% of revenue allocated to research and development.
• Employee Engagement: 92% of employees believe Lantheus operates with a high degree of integrity.

These figures demonstrate how Lantheus' mission, vision, and values translate into tangible business outcomes, driving both financial success and positive impact on patient care.

Lantheus Holdings, Inc. (LNTH) Core Values

Company operates with a set of core values that guide its actions and decisions. These values reflect Company's commitment to patients, customers, employees, and shareholders.

Here's an exploration of Company's core values:

Integrity

Company places a high value on integrity, emphasizing ethical conduct, honesty, and transparency in all its interactions. This commitment extends to how it interacts with healthcare professionals, patients, and its own employees. By upholding these standards, Company aims to build trust and credibility within the medical community and beyond. In 2024, this focus on integrity was evident in their compliance programs, which are designed to ensure adherence to both legal and ethical standards across all operations.

• Commitment to ethical conduct and transparency
• Building trust with healthcare professionals and patients
• Ensuring adherence to legal and ethical standards

Customer Focus

Company is dedicated to understanding and meeting the needs of its customers, primarily healthcare providers and patients. This involves not only providing high-quality products but also ensuring excellent service and support. The company actively seeks feedback to improve its offerings and tailor its solutions to better address the challenges faced by healthcare professionals in diagnostics and treatment. In 2024, this customer-centric approach was reflected in Company's investment in customer support resources and training programs, aimed at enhancing the overall customer experience.

• Dedication to meeting the needs of healthcare providers and patients
• Providing high-quality products with excellent service and support
• Seeking feedback to improve offerings and tailor solutions

Innovation

Company emphasizes the importance of innovation in driving its success and contributing to advancements in medical imaging and therapies. This includes investing in research and development to create new products and improve existing ones. By fostering a culture of innovation, Company aims to stay at the forefront of its industry and deliver cutting-edge solutions to improve patient outcomes. In 2024, Company's commitment to innovation was demonstrated through its continued investment in clinical trials and research partnerships, with a focus on developing novel imaging agents and therapies.

• Importance of innovation in driving success and contributing to advancements
• Investing in research and development to create new products
• Fostering a culture of innovation to deliver cutting-edge solutions

Collaboration

Company recognizes the value of collaboration in achieving its goals and fostering a positive work environment. This involves working closely with partners, healthcare professionals, and employees to share knowledge, resources, and expertise. By promoting teamwork and open communication, Company aims to leverage the collective intelligence of its stakeholders to drive innovation and improve patient care. In 2024, Company's emphasis on collaboration was evident in its partnerships with leading research institutions and healthcare organizations, aimed at advancing scientific knowledge and improving patient access to innovative therapies.

• Value of collaboration in achieving goals and fostering a positive work environment
• Working closely with partners, healthcare professionals, and employees
• Promoting teamwork and open communication to drive innovation

Accountability

Company holds itself accountable for its actions and decisions, taking responsibility for its performance and impact on stakeholders. This includes setting clear goals, measuring progress, and continuously seeking ways to improve. By embracing accountability, Company aims to build trust with its stakeholders and ensure that it operates in a responsible and sustainable manner. In 2024, Company's commitment to accountability was demonstrated through its transparent reporting practices and its efforts to track and measure its environmental, social, and governance (ESG) performance.

• Holding itself accountable for its actions and decisions
• Setting clear goals, measuring progress, and seeking ways to improve
• Embracing accountability to build trust and operate responsibly

To gain a broader understanding of Company's financial performance, consider exploring this resource: Breaking Down Lantheus Holdings, Inc. (LNTH) Financial Health: Key Insights for Investors